NU Hospital Group-Vaestra Goetalandsregionen

The site is investigating alternative antibiotic strategies for infections caused by resistant bacteria, aiming to improve safety and effectiveness of outpatient care.

• Evaluation of oral step‑down regimens for multidrug‑resistant urinary tract infections
• Comparison of penicillin versus cloxacillin for Staphylococcus aureus bacteraemia
• Assessment of local antimicrobial agents in healing diabetic foot ulcers linked to bacterial infection

Collaboration with regional microbiology laboratories enhances pathogen identification and supports personalized therapy.

Research here targets innovative treatments for acute heart conditions, focusing on optimizing pharmacologic management to reduce complications.

• Investigation of adenosine‑based therapy for Takotsubo cardiomyopathy
• Study of apixaban versus no antithrombotic therapy to prevent thromboembolic events
• Evaluation of renin inhibition effects on renal involvement in cardiovascular patients

Findings are intended to inform clinical guidelines for emergency and chronic cardiac care.

The department conducts trials to enhance maternal health, with a focus on outpatient labour induction as a safe alternative to hospital admission.

• Randomized assessment of outpatient versus inpatient induction of labour
• Monitoring of maternal and fetal outcomes following novel induction protocols

Results aim to expand options for women seeking less invasive delivery preparations at NU Hospital Group‑Vaestra Goetalandsregionen.

Clinical studies address blood‑related cancers, seeking to improve survival through targeted maintenance therapies and combination regimens.

• Maintenance treatment comparison after autologous stem cell transplant in newly diagnosed multiple myeloma
• Evaluation of acalabrutinib plus rituximab in untreated mantle cell lymphoma
• Assessment of tafasitamab added to rituximab‑lenalidomide for follicular lymphoma
• Monotherapy trial of etentamig in relapsed or refractory multiple myeloma

The research supports personalized therapy pathways for patients with hematologic malignancies.

Investigations focus on endocrine disorders, aiming to preserve organ function and improve quality of life through novel therapeutic approaches.

• Ixekizumab trial to preserve insulin secretion in newly diagnosed type 1 diabetes
• Aliskiren versus enalapril study in complement‑mediated C3 glomerulopathy
• Randomized evaluation of local antimicrobial dressings for diabetic foot ulcer healing

Outcomes may lead to new standards for managing hormonal and renal complications.

The site explores immune‑mediated conditions, testing agents that modulate inflammation and enhance vaccine responses, with an emphasis on clinical efficacy and safety.

• Tezepelumab trial assessing histologic and symptom improvement in eosinophilic esophagitis
• Immunity assessment after revaccination against varicella and measles in childhood cancer survivors
• Evaluation of complement activation reduction in C3 glomerulopathy as an immune‑related kidney disease

Findings will contribute to better management of allergic, autoimmune, and post‑cancer immunologic health.

Oncology research at the hospital targets a range of cancers, seeking to refine treatment based on molecular characteristics and disease stage.

• Adjuvant aspirin study in colorectal cancer patients with PIK3CA mutations
• Phase II trial for patients with recurrent non‑muscle invasive bladder cancer
• Pediatric cancer survivorship immunization monitoring
• Evaluation of tumor stage II‑III colon and rectal cancer outcomes

The work supports precision oncology initiatives across the Vaestra Goetalandsregionen.

Studies address symptom relief and healing processes, aiming to accelerate recovery through targeted therapeutic interventions.

• Time‑to‑healing assessment of novel antimicrobial dressings for diabetic foot ulcers
• Symptom improvement measurement in eosinophilic esophagitis with tezepelumab
• Long‑term safety monitoring across multiple trial cohorts

Results are intended to guide clinicians in managing chronic and acute symptom burdens.

The clinical program includes investigations of viral infections, focusing on antiviral efficacy and neuroprotection.

• Remdesivir efficacy trial during tick‑borne encephalitis infection
• Neuronal injury biomarker analysis in viral encephalitis patients

Outcomes may influence treatment protocols for emerging viral encephalitic diseases.